|
TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CIMETIDINE INCREASES ITS PLASMA CONCENTRATION AND HENCE BIOAVAILABILITY
|
ANTACIDS CAN DELAY & DECREASE ORAL ABSOPTION, AVOID MEDICINES WITHIN 2 HRS OF ANTACIDS
|
ANTACIDS CAN DELAY & DECREASE ORAL ABSOPTION, AVOID MEDICINES WITHIN 2 HRS OF ANTACIDS
|
MAY POTENTIALLY INCREASE THE RISK FOR ACETAMINOPHEN INDUCED HEPATOTOXICITY
|
INCREASED RISK OF MYOCARDIAL DEPRESSION
|
AMIODARONE SERUM LEVELS ARE DECREASED. PROLONGED ADMINISTRATION OF AMIODARONE IMPAIRES PHENYTOIN METABOLISM
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND PHENYTOIN LEADING TO A DECREASE IN THE TOTAL CONCENTRATION OF PHENYTOIN
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND PHENYTOIN LEADING TO A DECREASE IN THE TOTAL CONCENTRATION OF PHENYTOIN
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND PHENYTOIN LEADING TO A DECREASE IN THE TOTAL CONCENTRATION OF PHENYTOIN
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND PHENYTOIN LEADING TO A DECREASE IN THE TOTAL CONCENTRATION OF PHENYTOIN
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND PHENYTOIN LEADING TO A DECREASE IN THE TOTAL CONCENTRATION OF PHENYTOIN
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND PHENYTOIN LEADING TO A DECREASE IN THE TOTAL CONCENTRATION OF PHENYTOIN
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND PHENYTOIN LEADING TO A DECREASE IN THE TOTAL CONCENTRATION OF PHENYTOIN
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND PHENYTOIN LEADING TO A DECREASE IN THE TOTAL CONCENTRATION OF PHENYTOIN
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND PHENYTOIN LEADING TO A DECREASE IN THE TOTAL CONCENTRATION OF PHENYTOIN
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND PHENYTOIN LEADING TO A DECREASE IN THE TOTAL CONCENTRATION OF PHENYTOIN
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND PHENYTOIN LEADING TO A DECREASE IN THE TOTAL CONCENTRATION OF PHENYTOIN
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
CAUTION IS ADVISED SINCE CO-ADMINISTRATION OF DRUGS METABOLIZED BY CYTOCHROME P450 SYSTEM AND MACROLIDE ANTIBIOIC IS ASSOCIATED WITH ELEVATION IN PHENYTOIN SERUM LEVELS
|
CO-ADMINISTRATION WITH PHENYTOIN MAY RESULT IN INCREASED CAFFEINE ELIMINATION ; HIGHER DOSES OF CAFFEINE MAY BE NEEDED
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
H-2 RECEPTOR ANTAGONIST LIKE CIMETIDINE MAY INCREASE ITS SERUM CONCENTRATION
|
H-2 RECEPTOR ANTAGONIST LIKE CIMETIDINE MAY INCREASE ITS SERUM CONCENTRATION
|
SERUM LEVELS OF PHENYTOIN ARE INCREASED
|
POTENTIAL FOR CHANGE IN SERUM PHENYTOIN LEVELS
|
AT HIGH CONCENTRATION IN VITRO, CLOPIDOGREL INHIBITS P450IIC9, ACCORDINGLY IT MAY INTERFERE WITH THE METABOLISM OF PHENYTOIN
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|